A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor.
Sin-Chan P, Mumal I, Suwal T, Ho B, Fan X, Singh I, Du Y, Lu M, Patel N, Torchia J, Popovski D, Fouladi M, Guilhamon P, Hansford JR, Leary S, Hoffman LM, Mulcahy Levy JM, Lassaletta A, Solano-Paez P, Rivas E, Reddy A, Gillespie GY, Gupta N, Van Meter TE, Nakamura H, Wong TT, Ra YS, Kim SK, Massimi L, Grundy RG, Fangusaro J, Johnston D, Chan J, Lafay-Cousin L, Hwang EI, Wang Y, Catchpoole D, Michaud J, Ellezam B, Ramanujachar R, Lindsay H, Taylor MD, Hawkins CE, Bouffet E, Jabado N, Singh SK, Kleinman CL, Barsyte-Lovejoy D, Li XN, Dirks PB, Lin CY, Mack SC, Rich JN, Huang A. A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 2019 07 08; 36(1):51-67.e7.
-
Biomarkers, Tumor
-
Brain Neoplasms
-
Cell Cycle
-
Cell Transformation, Neoplastic
-
Chromosomes, Human, Pair 19
-
Chromosomes, Human, Pair 2
-
DNA Copy Number Variations
-
Enhancer Elements, Genetic
-
Epigenesis, Genetic
-
Gene Expression Regulation
-
Gene Regulatory Networks
-
Genetic Association Studies
-
Genetic Predisposition to Disease
-
Humans
-
MicroRNAs
-
Models, Biological
-
Multigene Family
-
Neoplasms, Germ Cell and Embryonal
-
N-Myc Proto-Oncogene Protein
-
Oncogenes
-
RNA-Binding Proteins
|